CAPRICOR THERAPEUTICS INC (CAPR)
US14070B3096 - Common Stock
Capricor Therapeutics Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
SAN DIEGO, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and...
Capricor Therapeutics Announces Pricing of Approximately $75 Million Public Offering of Common Stock
SAN DIEGO, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and...
Which stocks are moving after the closing bell on Wednesday?
The US market regular session of Wednesday is over, let's have a look at the top gainers and losers in the after hours session today.
Capricor Therapeutics Announces Proposed Public Offering of Common Stock
SAN DIEGO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and...
Capricor Therapeutics Announces Positive Long-Term Data from HOPE-2 OLE Study in Duchenne Muscular Dystrophy at 2024 World Muscle Society Congress
-Data Supports Deramiocel’s Sustained Efficacy and Safety in Treating DMD- -Improvements Seen in Multiple Cardiac and Skeletal Endpoints Demonstrating...
Capricor Therapeutics Announces Initiation of Rolling Submission of Biologics License Application (BLA) with U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy
-Company Plans to Complete Rolling BLA Submission by End of 2024; Application May be Eligible for Priority Review by FDA- SAN DIEGO, Oct. 09, 2024 ...
Tuesday Sector Leaders: Diagnostics, Biotechnology Stocks
June 2025 Options Now Available For Capricor Therapeutics (CAPR)
Capricor Therapeutics to Present Long-Term Data from HOPE-2 Open Label Extension Study at 2024 World Muscle Society Congress
SAN DIEGO, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and...
Capricor Therapeutics to Provide Duchenne Muscular Dystrophy Program Update on September 24, 2024
Investor Webcast on Tuesday, September 24, 2024 at 8:30 a.m. ET...
Capricor Therapeutics Signs Binding Term Sheet with Nippon Shinyaku for European Expansion and Commercialization of Deramiocel for the Treatment of Duchenne Muscular Dystrophy
-Capricor to Receive $15 Million Equity Investment at a 20% Premium, as well as $20 Million Upfront Payment upon Signing Definitive Agreement with up to...
Capricor Therapeutics to Present at Upcoming Investor and Scientific Conferences
SAN DIEGO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and...
Capricor Therapeutics to Present Second Quarter 2024 Financial Results and Recent Corporate Update on August 7
-Company to Host Conference Call, August 7, 2024 at 4:30 p.m. ET- SAN DIEGO, July 31, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a...